慢性肾脏病妊娠期贫血:综述与研究方向
本文综述了慢性肾脏病(CKD)合并妊娠时贫血与缺铁的诊断与治疗现状。缺铁性贫血可增加不良母婴结局风险,但在CKD孕妇中的患病率、病理生理及最佳治疗(口服/静脉铁剂、重组人促红素)尚不明确,作者据此提出研究优先方向。
要点
- CKD孕妇缺铁性贫血与不良母婴结局风险增加相关。
- CKD妊娠期缺铁和贫血的患病率、病理生理及治疗证据有限。
- 口服/静脉铁剂及重组人促红素的最佳管理方案尚待明确。
核心结论
- CKD合并妊娠时缺铁性贫血对不良结局的贡献程度未知,贫血管理存在诸多未解问题。
研究设计与样本
- 本文为综述,评估了CKD孕妇缺铁、贫血及营养缺乏的文献并指出知识缺口。
主要发现
- CKD和缺铁性贫血均增加不良母婴结局风险,包括母体发病率与死亡率、死产、围产期死亡、早产和低出生体重。
- CKD孕妇缺铁性贫血的患病率、病理生理及治疗所知甚少。
临床怎么用
- 临床需关注CKD孕妇的铁缺乏与贫血,但口服/静脉铁剂及重组人促红素的最佳方案尚未确立。
局限性
- 综述指出CKD妊娠期贫血领域证据有限,许多管理问题尚无答案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD), anemia, and iron deficiency are global health issues affecting individuals in both high-income and low-income countries. In pregnancy, both CKD and iron deficiency anemia increase the risk of adverse maternal and neonatal outcomes, including increased maternal morbidity and mortality, stillbirth, perinatal death, preterm birth, and low birthweight. However, it is unknown to which extent iron deficiency anemia contributes to adverse outcomes in CKD pregnancy. Furthermore, little is known regarding the prevalence, pathophysiology, and treatment of iron deficiency and anemia in pregnant women with CKD. Therefore, there are many unanswered questions regarding optimal management with oral or i.v. iron and recombinant human erythropoietin (rhEPO) in these women. In this review, we present a short overview of the (patho)physiology of anemia in healthy pregnancy and in people living with CKD. We present an evaluation of the literature on iron deficiency, anemia, and nutritional deficits in pregnant women with CKD; and we evaluate current knowledge gaps. Finally, we propose research priorities regarding anemia in pregnant women with CKD.
引用
- de Jong MFC, Nemeth E, Rawee P, et al. Anemia in Pregnancy With CKD. Kidney Int Rep. 2024. PMID: 38707831. doi:10.1016/j.ekir.2024.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。